Zyclara (imiquimod)
- Region
- 🇪🇺 EU
- Active substance
- imiquimod
- Company
- Viatris Healthcare Limited
- Status
- Authorised
- Therapeutic area
- Keratosis; Keratosis, Actinic
- CHMP opinion
- Thu 21 Jun 2012
- EU approval
- Thu 23 Aug 2012
- Application
- EMEA/H/C/002387
- ATC
- D06BB10
- Official record
- www.ema.europa.eu
Indication
Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
Follow Zyclara
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.